CO5170533A1 - Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios - Google Patents

Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios

Info

Publication number
CO5170533A1
CO5170533A1 CO99078241A CO99078241A CO5170533A1 CO 5170533 A1 CO5170533 A1 CO 5170533A1 CO 99078241 A CO99078241 A CO 99078241A CO 99078241 A CO99078241 A CO 99078241A CO 5170533 A1 CO5170533 A1 CO 5170533A1
Authority
CO
Colombia
Prior art keywords
alkyl
tar1
6alkyl
piperidin
cycloalkyl
Prior art date
Application number
CO99078241A
Other languages
English (en)
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Green Darren Victor Steven
Holman Stuart
Lain Maclean Jack Torquil
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morris
Grahame Ramsden Nigel
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5170533A1 publication Critical patent/CO5170533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto de fórmula I:<EMI FILE="99078241_1" ID="1" IMF=JPEG >caracterizado porque R1 y R2 independientemente representan (i) alquiloC1-C6, cicloalquiloC3-8 o alquiloC1-3 cicloalquiloC3-8, o tal grupo en el cual el alquilo o cicloalquilo está substituido por uno o más grupos halógenos, -CN, nitro, hidroxi o OalquiloC1-6;(ii) -(CH2)e Ar1 o -(CH2)e OAr1; o NR1R2 juntos representan pirrolidinilo, piperidinilo, piperazinilo, tiomorfolinilo, morfolinilo o azepinilo, o tal grupo fusionado a un anillo benceno, opcionalmente substituido por uno o más grupos -(CO)n(CH2)tAr1; -(CO)nalquiloC1-6Ar1Ar2, -(CO)nalquiloC1-6, -(CH2)rOH, -(CH2)rO(CH2)pOH, -(CH2)rOalquiloC1-6, -O(CH2)tAr1, -(CH2)rSO2Ar1, piperidin-1-il, -(CH2)tCONR8R9, -NR10(CO)n(CH2)tAr1, -NR10(CO)nalquiloC1-3cicloalquilo C3-6, -NR10(CO)nalquiloC1-6dicicloalquiloC3-6, -CONR10(CH2)tAr1, halógeno, -NHSO2alquiloC1-6, -SO2NR10 R11, -SO2alquiloC1-6 o -SO2AR2;R3 representa alquilo C1-C6NHC(=NH)NH2, -alqueniloC2-6NHC(=NH)NH2, alquinilo C2-6NHC(=NH)NH2, alquilo C1-6NR14R18, -(CH2)hCONR14R18, -(CH2)hCOalquiloC1-6, (CH2)dCHNR18CONR20R21, -(CH2)mNR18CONR14R18, -(CH2)dNR18Ar3, -(CH2)dCONR18Ar3, -(CH2)hCOOR18, -(CH2)cAr3, -O(CH2)cAr3, -(CH2)dCO(CH2)sAr3 o -(CH2)dOAr3);o R3 representa -(CH2)c-2,4-imidazolidinodiona, -(CH2)c(piperidin-4-il), -(CH2)c(piperidin-3-il), -(CH2)c(piperidin-2-il), -(CH2)c(morfolin-3-il) o (CH2)c(morfolin-2-il) opcionalmente sustituido en nitrógeno por -(CO)falquiloC1-6, -(CO)f(CH2)cAr2 o -C(=NH)NH2;o R3 representa -(CH2)zdibenzofurano opcionalmente sustituido con alquiloC1-6, ó halogeno, ó R3 representa -(CH2)c-tioxanten-9-ona;R4 representa hidrógeno, alquiloC1-6, alquiloC1-3cicloalquiloC3-6, -(CH2)qAr2, -alquilo C1-4, -X-R7, -alquiloC1-4SO2alquiloC1-4, -alquiloC1-6NR12R13 o -alquiloC1-6NR12COalquilo C1-6;R5 representa hidrógeno, o R4R5 junto con el átomo de carbono al cual están unidos forman un anillo cicloalquiloC5-7;R6 representa hidrógeno ó alquilo C1-6 ó R6 y R4 junto con los átomos de nitrógeno o carbono al cual están respectivamente unidos, forman un anillo pirrolidina;R7 representa hidrógeno, -(CH2)wN12R13, -(CH2)uAr2 o -(CH2)wNR12COalquiloC1-6; ...
CO99078241A 1998-12-18 1999-12-15 Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios CO5170533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
CO5170533A1 true CO5170533A1 (es) 2002-06-27

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99078241A CO5170533A1 (es) 1998-12-18 1999-12-15 Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios

Country Status (26)

Country Link
US (1) US6867192B1 (es)
EP (1) EP1140837B1 (es)
JP (1) JP4431282B2 (es)
KR (1) KR20010101258A (es)
CN (1) CN1330637A (es)
AR (1) AR023727A1 (es)
AT (1) ATE273954T1 (es)
AU (1) AU760169B2 (es)
BR (1) BR9916282A (es)
CA (1) CA2355630A1 (es)
CO (1) CO5170533A1 (es)
CZ (1) CZ20012209A3 (es)
DE (1) DE69919580T2 (es)
ES (1) ES2226488T3 (es)
GB (1) GB9828074D0 (es)
GT (1) GT199900217A (es)
HK (1) HK1038744A1 (es)
HU (1) HUP0104867A3 (es)
IL (1) IL142908A0 (es)
NO (1) NO20012995L (es)
NZ (1) NZ511478A (es)
PE (1) PE20001387A1 (es)
PL (1) PL348059A1 (es)
TR (1) TR200101709T2 (es)
WO (1) WO2000037444A1 (es)
ZA (1) ZA200103948B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
CA2525934A1 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BR112012019383A2 (pt) 2010-02-02 2017-09-12 Pixtronix Inc Circuitos para controlar aparelho de exibição
JP2013519121A (ja) 2010-02-02 2013-05-23 ピクストロニックス・インコーポレーテッド 低温封孔流体充填ディスプレイ装置を製造するための方法
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2013215332A1 (en) 2012-01-31 2014-09-04 Genentech, Inc. Anti-Ig-E M1' antibodies and methods using same
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
MY187552A (en) 2015-07-08 2021-09-29 Axerovision Inc Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
CN109563144B (zh) * 2016-06-01 2023-03-28 雅斯娜 化合物
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2022084747A1 (en) * 2020-10-21 2022-04-28 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
CA2291708A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE69833654T2 (de) * 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
DE69820614T2 (de) 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate

Also Published As

Publication number Publication date
EP1140837A1 (en) 2001-10-10
CA2355630A1 (en) 2000-06-29
EP1140837B1 (en) 2004-08-18
CN1330637A (zh) 2002-01-09
NO20012995L (no) 2001-08-15
HUP0104867A2 (hu) 2002-04-29
US6867192B1 (en) 2005-03-15
GB9828074D0 (en) 1999-02-17
AR023727A1 (es) 2002-09-04
DE69919580T2 (de) 2005-09-01
AU3039100A (en) 2000-07-12
CZ20012209A3 (cs) 2001-09-12
ES2226488T3 (es) 2005-03-16
TR200101709T2 (tr) 2001-12-21
JP2002533326A (ja) 2002-10-08
HUP0104867A3 (en) 2002-06-28
PE20001387A1 (es) 2000-12-22
IL142908A0 (en) 2002-04-21
ZA200103948B (en) 2002-11-15
BR9916282A (pt) 2001-10-02
NZ511478A (en) 2003-08-29
HK1038744A1 (zh) 2002-03-28
GT199900217A (es) 2001-06-09
JP4431282B2 (ja) 2010-03-10
WO2000037444A1 (en) 2000-06-29
KR20010101258A (ko) 2001-11-14
ATE273954T1 (de) 2004-09-15
AU760169B2 (en) 2003-05-08
DE69919580D1 (de) 2004-09-23
PL348059A1 (en) 2002-05-06
NO20012995D0 (no) 2001-06-15

Similar Documents

Publication Publication Date Title
CO5170533A1 (es) Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
CO6160266A2 (es) Derivado de oxopirazina y herbicida
PE20160217A1 (es) Analogos de carba-nucleosidos sustituidos con 2&#39;-fluoro antivirales
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
PE20070097A1 (es) Agonistas del receptor de niacina y composiciones que contienen tales compuestos
AR084280A1 (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
MY140012A (en) Heterocylic substituted phenyl methanones
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
TW200732284A (en) Amine compound and pharmaceutical use thereof
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
CO5690579A2 (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos
CO5660292A2 (es) Pirimidinas 2-sustituidas
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO5540387A2 (es) Nuevos derivados de oxazolidinonas como antibacterianos
AR050153A1 (es) Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos
ES2570766T3 (es) Derivados del 1-bencil-3-hidroximetilindazol y su utilización en el tratamiento de enfermedades basadas en la expresión de MCP-1 y CX3CR1
EA200971063A1 (ru) Ариламидпиримидоновые соединения
AR066603A1 (es) Derivados de arilamida pirimidona
DE69925472D1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
RS50527B (sr) Derivati indanil-piperazina, proces njihove izrade i farmaceutske smeše koje ih sadrže
RU2008143546A (ru) Тиазолилдигидрохиназолины

Legal Events

Date Code Title Description
FC Application refused